<p>GoodRx Holdings, Inc.（纳斯达克代码：GDRX - 获取免费报告）在目前覆盖该公司的十二家评级机构中获得了 “持有” 的共识评级，MarketBeat 报道。七位股票研究分析师给予该股票持有评级，五位分析师对该公司发布了买入评级。在过去一年中，覆盖该股票的经纪公司平均目标价为 5.80 美元。</p>
<ul>
<li>Wegovy 与 Zepbound：谁赢得 GLP-1 药物之战？</li>
</ul>
<p>几位股票研究分析师最近对该公司发表了看法。德意志银行重新发布了 “持有” 评级，并在 8 月 11 日的研究报告中对 GoodRx 的股票设定了 6.00 美元的目标价。雷蒙德·詹姆斯金融公司在 8 月 8 日的研究报告中将 GoodRx 的评级从 “强力买入” 下调至 “跑赢大盘”。最后，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了 GoodRx 的 “持有（c-）” 评级。</p>
<p><strong>查看我们对 GoodRx 的最新股票分析</strong></p>
<h2>GoodRx 股价下跌 1.8%</h2>
<ul>
<li>这只医疗保健股票因增长 160% 而备受关注</li>
</ul>
<p>GDRX 股票在周五开盘价为 3.83 美元。该股票的市值为 13.3 亿美元，市盈率为 38.30，PEG 比率为 1.70，贝塔值为 1.23。该股票的 50 日移动平均线为 4.21 美元，200 日移动平均线为 4.37 美元。公司的流动比率为 4.21，速动比率为 4.21，债务股本比率为 0.75。GoodRx 的一年低点为 3.31 美元，一年高点为 6.97 美元。</p>
<p>GoodRx（纳斯达克代码：GDRX - 获取免费报告）最近于 8 月 6 日发布了季度财报。该公司报告本季度每股收益为 0.09 美元，低于共识预期的 0.10 美元（差额为 0.01 美元）。该公司本季度的收入为 2.0307 亿美元，而分析师预期为 2.0572 亿美元。GoodRx 的净利润率为 4.33%，股本回报率为 8.86%。该公司的季度收入同比增长 1.2%。在去年同期，该公司每股收益为 0.08 美元。股票研究分析师平均预测 GoodRx 本年度每股收益将达到 0.13 美元。</p>
<h2>内部人士下注</h2>
<ul>
<li>基因疗法：为什么单次治疗要花费数百万？</li>
</ul>
<p>在其他新闻中，主要股东 Equity Vii L.P. Spectrum 于 10 月 15 日（星期三）出售了 23,771 股该公司的股票。股票以平均价格 4.00 美元出售，总交易额为 95,084.00 美元。该交易在证券交易委员会的备案中披露，相关文件可在此链接查看。内部人士持有该公司 4.53% 的股份。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金最近调整了对 GDRX 的持股。CWA Asset Management Group LLC 在第一季度购买了价值约 292,000 美元的 GoodRx 新头寸。德克萨斯州教师退休系统在第一季度购买了价值约 218,000 美元的 GoodRx 新头寸。Hohimer Wealth Management LLC 在第一季度将其在 GoodRx 的持股增加了 8.2%。Hohimer Wealth Management LLC 现在拥有 35,218 股该公司股票，价值 155,000 美元，此前在上个季度又购买了 2,658 股。SBI Securities Co. Ltd. 在第一季度将其在 GoodRx 的持股增加了 13.8%。SBI Securities Co. Ltd. 现在拥有 22,624 股该公司股票，价值 100,000 美元，此前在上个季度又购买了 2,748 股。最后，安联资产管理公司在第一季度将其在 GoodRx 的持股增加了 20.3%。安联资产管理公司现在拥有 278,077 股该公司股票，价值 1,226,000 美元，此前在上个季度又购买了 46,900 股。对冲基金和其他机构投资者持有该公司 63.77% 的股份。</p>
<h2>GoodRx 公司简介</h2>
<p>（获取免费报告）</p>
<p>GoodRx Holdings, Inc. 及其子公司提供信息和工具，使消费者能够比较价格并节省在美国的处方药购买费用。该公司运营一个价格比较平台，为消费者提供经过筛选的、地理相关的处方定价和谈判价格的访问。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票</li>
<li>什么是股息挑战者？</li>
<li>这家 AI 芯片巨头可能是市场下一个大赢家</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>博通签署 OpenAI 合同：为什么这对 AVGO 股票是一个巨大的胜利</li>
<li>CD 计算器：定期存款计算器</li>
<li>机构正在推动 CrowdStrike 的下一个上涨阶段</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 GoodRx 吗？</h2>
<p>在考虑 GoodRx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 GoodRx 并不在名单上。</p>
<p>虽然 GoodRx 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GDRX

<p>GoodRx Holdings, Inc.（纳斯达克代码：GDRX）获得了十二家券商的共识评级为 “持有”，其中七位分析师给予 “持有” 评级，五位分析师给予 “买入” 评级。平均目标价为 5.80 美元。该股票开盘价为 3.83 美元，市值为 13.3 亿美元。GoodRx 报告上个季度每股收益为 0.09 美元，未达到预期，收入为 2.0307 亿美元。主要股东 Equity Vii L.P. Spectrum 以每股 4.00 美元出售了 23,771 股。机构投资者持有该公司 63.77% 的股份</p>

<p>GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has received a consensus rating of &#34;Hold&#34; from the twelve ratings firms that are currently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $5.80.</p>
<div class="lb-trans"><p>GoodRx Holdings, Inc.（纳斯达克代码：GDRX - 获取免费报告）在目前覆盖该公司的十二家评级机构中获得了 “持有” 的共识评级，MarketBeat 报道。七位股票研究分析师给予该股票持有评级，五位分析师对该公司发布了买入评级。在过去一年中，覆盖该股票的经纪公司平均目标价为 5.80 美元。</p>
</div><ul>
<li>Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?</li>
</ul>
<div class="lb-trans"><ul>
<li>Wegovy 与 Zepbound：谁赢得 GLP-1 药物之战？</li>
</ul>
</div><p>Several equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reissued a &#34;hold&#34; rating and issued a $6.00 price target on shares of GoodRx in a research note on Monday, August 11th. Raymond James Financial cut GoodRx from a &#34;strong-buy&#34; rating to an &#34;outperform&#34; rating in a research note on Friday, August 8th. Finally, Weiss Ratings reissued a &#34;hold (c-)&#34; rating on shares of GoodRx in a research note on Wednesday, October 8th.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司发表了看法。德意志银行重新发布了 “持有” 评级，并在 8 月 11 日的研究报告中对 GoodRx 的股票设定了 6.00 美元的目标价。雷蒙德·詹姆斯金融公司在 8 月 8 日的研究报告中将 GoodRx 的评级从 “强力买入” 下调至 “跑赢大盘”。最后，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了 GoodRx 的 “持有（c-）” 评级。</p>
</div><p><strong>View Our Latest Stock Analysis on GoodRx</strong></p>
<div class="lb-trans"><p><strong>查看我们对 GoodRx 的最新股票分析</strong></p>
</div><h2>GoodRx Trading Down 1.8%</h2>
<div class="lb-trans"><h2>GoodRx 股价下跌 1.8%</h2>
</div><ul>
<li>This healthcare stock making a buzz with 160% growth</li>
</ul>
<div class="lb-trans"><ul>
<li>这只医疗保健股票因增长 160% 而备受关注</li>
</ul>
</div><p>Shares of GDRX stock opened at $3.83 on Friday. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of 38.30, a PEG ratio of 1.70 and a beta of 1.23. The stock has a 50-day moving average of $4.21 and a 200-day moving average of $4.37. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.75. GoodRx has a 1-year low of $3.31 and a 1-year high of $6.97.</p>
<div class="lb-trans"><p>GDRX 股票在周五开盘价为 3.83 美元。该股票的市值为 13.3 亿美元，市盈率为 38.30，PEG 比率为 1.70，贝塔值为 1.23。该股票的 50 日移动平均线为 4.21 美元，200 日移动平均线为 4.37 美元。公司的流动比率为 4.21，速动比率为 4.21，债务股本比率为 0.75。GoodRx 的一年低点为 3.31 美元，一年高点为 6.97 美元。</p>
</div><p>GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). The company had revenue of $203.07 million during the quarter, compared to analyst estimates of $205.72 million. GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The company's quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.08 EPS. On average, equities research analysts forecast that GoodRx will post 0.13 earnings per share for the current year.</p>
<div class="lb-trans"><p>GoodRx（纳斯达克代码：GDRX - 获取免费报告）最近于 8 月 6 日发布了季度财报。该公司报告本季度每股收益为 0.09 美元，低于共识预期的 0.10 美元（差额为 0.01 美元）。该公司本季度的收入为 2.0307 亿美元，而分析师预期为 2.0572 亿美元。GoodRx 的净利润率为 4.33%，股本回报率为 8.86%。该公司的季度收入同比增长 1.2%。在去年同期，该公司每股收益为 0.08 美元。股票研究分析师平均预测 GoodRx 本年度每股收益将达到 0.13 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>Gene therapy: Why does it cost millions for a single treatment?</li>
</ul>
<div class="lb-trans"><ul>
<li>基因疗法：为什么单次治疗要花费数百万？</li>
</ul>
</div><p>In other news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the business's stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total transaction of $95,084.00. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. Insiders own 4.53% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，主要股东 Equity Vii L.P. Spectrum 于 10 月 15 日（星期三）出售了 23,771 股该公司的股票。股票以平均价格 4.00 美元出售，总交易额为 95,084.00 美元。该交易在证券交易委员会的备案中披露，相关文件可在此链接查看。内部人士持有该公司 4.53% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds have recently modified their holdings of GDRX. CWA Asset Management Group LLC purchased a new position in shares of GoodRx during the first quarter valued at approximately $292,000. Teacher Retirement System of Texas purchased a new position in shares of GoodRx during the first quarter valued at approximately $218,000. Hohimer Wealth Management LLC boosted its position in shares of GoodRx by 8.2% during the first quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company's stock valued at $155,000 after buying an additional 2,658 shares during the last quarter. SBI Securities Co. Ltd. boosted its position in shares of GoodRx by 13.8% during the first quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company's stock valued at $100,000 after buying an additional 2,748 shares during the last quarter. Finally, Allianz Asset Management GmbH boosted its position in shares of GoodRx by 20.3% during the first quarter. Allianz Asset Management GmbH now owns 278,077 shares of the company's stock valued at $1,226,000 after buying an additional 46,900 shares during the last quarter. Hedge funds and other institutional investors own 63.77% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对 GDRX 的持股。CWA Asset Management Group LLC 在第一季度购买了价值约 292,000 美元的 GoodRx 新头寸。德克萨斯州教师退休系统在第一季度购买了价值约 218,000 美元的 GoodRx 新头寸。Hohimer Wealth Management LLC 在第一季度将其在 GoodRx 的持股增加了 8.2%。Hohimer Wealth Management LLC 现在拥有 35,218 股该公司股票，价值 155,000 美元，此前在上个季度又购买了 2,658 股。SBI Securities Co. Ltd. 在第一季度将其在 GoodRx 的持股增加了 13.8%。SBI Securities Co. Ltd. 现在拥有 22,624 股该公司股票，价值 100,000 美元，此前在上个季度又购买了 2,748 股。最后，安联资产管理公司在第一季度将其在 GoodRx 的持股增加了 20.3%。安联资产管理公司现在拥有 278,077 股该公司股票，价值 1,226,000 美元，此前在上个季度又购买了 46,900 股。对冲基金和其他机构投资者持有该公司 63.77% 的股份。</p>
</div><h2>GoodRx Company Profile</h2>
<div class="lb-trans"><h2>GoodRx 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.</p>
<div class="lb-trans"><p>GoodRx Holdings, Inc. 及其子公司提供信息和工具，使消费者能够比较价格并节省在美国的处方药购买费用。该公司运营一个价格比较平台，为消费者提供经过筛选的、地理相关的处方定价和谈判价格的访问。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than GoodRx</li>
<li>What Are Dividend Challengers?</li>
<li>This AI Chip Giant Could Be the Market’s Next Big Winner</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Institutions Are Fueling CrowdStrike’s Next Leg Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票</li>
<li>什么是股息挑战者？</li>
<li>这家 AI 芯片巨头可能是市场下一个大赢家</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>博通签署 OpenAI 合同：为什么这对 AVGO 股票是一个巨大的胜利</li>
<li>CD 计算器：定期存款计算器</li>
<li>机构正在推动 CrowdStrike 的下一个上涨阶段</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=GDRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GoodRx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 GoodRx 吗？</h2>
</div><p>Before you consider GoodRx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 GoodRx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 GoodRx 并不在名单上。</p>
</div><p>While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 GoodRx 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

GoodRx Holdings, Inc.（纳斯达克股票代码：GDRX）被券商给予平均 “持有” 评级